Beware of risks when using non-steroidal anti-inflammatory drugs
THE South African Health Products Regulatory Authority (SAHPRA) cautions consumers about the risk of adverse effects when using non-steroidal anti-inflammatory drugs (NSAIDs).
NSAIDs are a group of medicines used for their pain-relieving and fever-reducing effects. They are available both over-the-counter (OTC) and on prescription, and are used as single medicines and in combination with other medicines.
NSAIDs include aspirin, ibuprofen, diclofenac, indomethacin, ketorolac, sulindac, lornoxicam, meloxicam, piroxicam, tenoxicam, naproxen, mefenamic acid, celecoxib, rofecoxib, parecoxib and valdecoxib. While considered safe when taken as directed, NSAIDs can cause stomach bleeding, may reduce kidney function, and may occasionally lead to heart attacks or strokes. These risks are higher with higher doses and/or when used for a longer period than recommended, and in patients who have pre-existing stomach problems, or have heart or kidney diseases.
If you take low-dose aspirin for protection against heart attacks and strokes, be advised that some NSAIDs can interfere with that protective effect. If you have heart disease or high blood pressure, consult a healthcare provider before using an NSAID.
Please inform your healthcare provider of any existing heart condition, known kidney problems or pre-existing stomach condition when seeking treatment.
Prescription NSAIDs are an important treatment for the symptoms of many debilitating conditions, including osteoarthritis, rheumatoid arthritis, gout, and other rheumatological and painful conditions.
OTC NSAIDs are used to temporarily reduce fever and to treat minor aches and pains such as headaches, toothaches, backaches, muscular aches, tendonitis and strains.
Consumers are urged to read the patient information leaflet for both OTC and prescription medicines, as it provides important safety information.
SAHPRA advises consumers to seek medical help if they experience stomach bleeding or symptoms that might signal heart problems or a stroke, such as chest pain, trouble breathing, sudden weakness in one part or side of the body, or sudden slurred speech while on NSAIDs.
Health professionals in South Africa are urged to report any adverse reactions to the National Adverse Drug Event Monitoring Centre at 021 4471 618 or the SAHPRA pharmacovigilance office at 012 3959 133, or use the reporting form which can be accessed at http://www.mccza.com/documents/14ed44a46.04_ ARF1_Jul16_v4.pdf and emailed to adr@health.gov.za Portia Nkambule Acting chief executive SAHPRA